Epilepsy

Epilepsy Awareness Month: Increasing Knowledge, Support and Advocacy

Vanco Vlastimil (��ֳ� S.A.) — Wed, 22 Nov 2023 10:57:33 +0000

Epilepsy Awareness Month: Increasing Knowledge, Support and Advocacy

Nick Francis, Global Communications & Company Reputation

Vanco Vlastimi… Wed 22/11/2023 - 11:57

In November, ��ֳ� joins the world in recognizing Epilepsy Awareness Month, which commenced on November 1st with International Lennox-Gastaut syndrome (LGS) Awareness Day. More than one million children and adults worldwide live with LGS, a severe, rare epilepsy syndrome that is often difficult to treat.

At ��ֳ�, we have a legacy commitment to the epilepsy community and remain dedicated to developing better solutions that address unmet family needs. Through our engagement with people living with epilepsies, like LGS, we often hear that it can be isolating — both physically and mentally for patients and caregivers. This risk underscores the critical importance of a strong sense of community and network of support that patient advocacy groups provide.

With recruitment support from the LGS Foundation (LGSF), ��ֳ� conducted a caregiver advisory board to better identify key issues affecting the needs of caregivers and their diagnosed loved ones through the journey of diagnosis, management, and treatment. Research findings were presented at NORD’s Rare Disease and Orphan Products Breakthrough Summit. With more than 900 rare disease advocates, experts, and stakeholders from around the world present, LGS was represented in the exhibit hall along with other pressing issues facing the rare disease community.

The research findings presented at the Breakthrough Summit highlighted the challenges faced by caregivers of people with LGS, from navigating multiple misdiagnoses to feeling overwhelmed by the complexity of the condition. Caregivers underscored the importance of early diagnosis, a trustworthy care team and peer-to-peer support groups to better care for someone with LGS. When asked about educational resources, patient advocacy groups, especially the LGSF, were the most valued source of information used by caregivers of people with LGS.

“The research findings we presented at NORD highlight the importance of supporting and connecting caregivers and families who live with the challenges of epilepsy and seizure disorders every day. As an additional outcome of this research, we launched Shine Forward with LGS (www.shineforwardwithlgs.com) as a complimentary resource to LGSF, to provide education, tips, and tools to support the entire LGS family, built by caregivers, for caregivers.” – Ross Lu, Study Investigator, Epilepsy & Rare Syndromes at ��ֳ�

“As demonstrated by the insights presented at NORD, supporting the epilepsy community extends well beyond treating the seizures. Extending care support services and holistic programs to persons living with epilepsy and their families is essential.” – Andrea Wilkinson, Study Investigator and Global Patient Engagement, Epilepsy & Rare Syndromes at ��ֳ�

To kick off Epilepsy Awareness Month, our global and US teams also participated in the 11th Annual Epilepsy Awareness Day at Disneyland^® in California to bring expert health providers, disease education and solutions to patients and caregivers. With the backdrop of fun and festivities for children and their families, this event provides an opportunity to unite thousands from the epilepsy community year after year.

“Epilepsy Awareness Day at Disneyland brings many leaders and families together from the epilepsy and rare syndromes community. Having the time and space to engage in a meaningful way is quite special.” – Laurie Bailey, US Patient Partnership Lead, Corporate Affairs at ��ֳ�

Epilepsy is one of the most common neurological disorders, affecting people of all ages. ��ֳ� is committed to transforming outcomes for people living with epilepsy and rare epileptic syndromes such as LGS. We are honored to share these special and meaningful moments with patients, their loved ones, and the advocacy community leading up to and during Epilepsy Awareness Month. It is a critical reminder of the significant unmet needs that remain and the importance of our work today and tomorrow.

solutions

859 Likes

Sudden Unexpected Death in Epilepsy: our commitment to supporting families and patients

Vanco Vlastimil (��ֳ� S.A.) — Wed, 18 Oct 2023 07:00:59 +0000

Sudden Unexpected Death in Epilepsy: our commitment to supporting families and patients

Judith Luker, Patient Engagement, Epilepsy and Rare Syndromes

Vanco Vlastimi… Wed 18/10/2023 - 09:00

SUDEP, or Sudden Unexpected Death in Epilepsy, refers to the unexplained death of a person with epilepsy who is otherwise healthy. It is a leading cause of epilepsy-related deaths. SUDEP Action Day, created by the charity SUDEP Action in 2014 and observed each October, plays a crucial role in raising awareness about this silent but deadly consequence of epilepsy bringing organisations worldwide together to help increase awareness of SUDEP and empower people with epilepsy.

While no one knows exactly what the mechanisms are when SUDEP occurs, there are certain factors that increase the risk of occurrence, such as the frequency of generalized tonic-clonic seizure (GTCS) and failure to adequately control treatment-resistant seizures. Research has shown that controlling seizures may lower the chance of SUDEP.

Although significant progress has been made during the past year in the understanding of SUDEP mechanisms and investigation of numerous potential biomarkers, we are still missing reliable predictors of SUDEP beyond the well-established clinical risk factors. To patients and families, SUDEP is an unthinkable aspect of living with epilepsy, and this is why we are committed to supporting the patient community on SUDEP-related issues in every way we can. We are investing in SUDEP research and are working to contribute further to the published literature in this area. We are also collaborating with other organizations on projects relevant to SUDEP; our work with Neurava, a medical device start-up, is a good example. Neurava is working on translating the discovery of a potential mechanism of action behind SUDEP into a first-of-its-kind smart wearable device capable of identifying and alerting for seizures and impending SUDEP risk - a device with the potential to save lives, and which we are proud to support in its development.

In another recent collaboration, ��ֳ� participated in an advisory workgroup with the Child Neurology Foundation in the US, along with 20 other organizations, on its Clinical Toolkit for Preventing Epilepsy Deaths. This toolkit includes resources raising awareness of potential causes of death among people with epilepsy to help individuals take preventative measures to mitigate the risk, as it is known that many epilepsy deaths could be prevented. The goal of the toolkit is to educate patients and healthcare professionals about epilepsy and address epilepsy mortality risk factors. On the Preventing Epilepsy Deaths toolkit website physicians can find materials to help them discuss preventative measures with their patients.

This year’s theme for SUDEP Action Day is #MySafetyMatters – highlighting how important it is that the epilepsy community takes action to help people with epilepsy to live as safely as possible. Putting the patient’s voice first is an important part of working at ��ֳ� and central to my role. Working closely with patients and patient organisations to understand their feelings about how the SUDEP conversation should happen, has deepened my understanding of this incredibly important and sensitive topic. At ��ֳ� we have a responsibility to do as much as we can to advance the conversation around SUDEP research, preventative care, and the needs of families.

solutions

SUDEP Sudden Unexpected Death in Epilepsy Neurology Epilepsy

407 Likes

��ֳ� welcomes the epilepsy treatment updates to the WHO Model List of Essential Medicines

Vanco Vlastimil (��ֳ� S.A.) — Mon, 31 Jul 2023 09:19:03 +0000

��ֳ� welcomes the epilepsy treatment updates to the WHO Model List of Essential Medicines

Michael Fürst, Social Business, ��ֳ�

Vanco Vlastimi… Mon 31/07/2023 - 11:19

At ��ֳ�, we believe everyone deserves to live the best life that they can – as free as possible from the challenges and uncertainty of disease. We develop solutions across neurology, immunology, and other areas where our expertise, innovation, and ambition align with the needs of those who live with severe diseases. ��ֳ� has a rich heritage in epilepsy, with over 30 years of experience in the research, development and delivery of antiseizure medications. As a company with a long-term commitment to epilepsy research, we want to contribute to solutions that address unmet medical needs of all patients living with epilepsy.

��ֳ� welcomes the inclusion of levetiracetam in the World Health Organization Model List of Essential Medicines (WHO EML), which we hope will result in an opportunity to widen the treatment options for people living with epileptic seizures around the world. To express our support for levetiracetam’s inclusion on the WHO Essential Medicines List, ��ֳ� provided a positive letter to the WHO Secretariat of the Expert Committee on the Selection and Use of Essential Medicines, signed by our CEO Jean-Christophe Tellier and Chief Medical Officer Iris Loew-Friedrich.

We are committed to improving access to quality care and medicines for people with epilepsy. Nearly 80% of people with epilepsy live in low- and middle-income countries (LMIC), where treatment gaps exceed 75% in most low-income countries and 50% in most middle-income countries, despite the effectiveness of available antiseizure medicines. To read more about our commitment, visit our Integrated Annual Report.

The World Health Organization (WHO) Model List of Essential Medicines

Essential medicines are those that satisfy the priority health care needs of a population. They are selected with due regard to disease prevalence and public health relevance, evidence of efficacy and safety and comparative cost-effectiveness. They are intended to be available in functioning health systems at all times, in appropriate dosage forms, of assured quality and at prices individuals and health systems can afford.

The WHO Model List of Essential Medicines is intended as a guide for countries or regional authorities to adopt or adapt in accordance with local priorities and treatment guidelines for the development and updating of national essential medicines lists. Selection of a limited number of medicines as essential, taking into consideration national disease burden and clinical need, can lead to improved access through streamlined procurement and distribution of quality-assured medicines, support more rational or appropriate prescribing and use and lower costs for both health care systems and for patients.

about ucb

World Health Organization Model List of Essential Medicines Epilepsy Neurology Patients

346 Likes

Meeting unmet needs in epilepsy management through digital health technological solutions

eCMSadmin — Wed, 01 Sep 2021 08:00:00 +0000

Meeting unmet needs in epilepsy management through digital health technological solutions

Cynthia Dilley, Global Epilepsy Strategy

eCMSadmin Wed 01/09/2021 - 10:00

Over the last decade, we have seen significant progress in the development of anti-seizure medications (ASMs), and there are now over a dozen options available for people living with epilepsy. While we have seen advances in epileptic seizure control, there is still a lot more that can be done to help address unmet needs in epilepsy management for both patients and healthcare professionals (HCPs).

As a pharmaceutical company with a significant heritage in epilepsy, we can leverage our leadership to utilize the resources we have available to equip epilepsy community with the tools to address these challenges. In addition to our extensive research and development capabilities, new health technological solutions can provide much needed support to optimize a patient’s journey. Leveraging digital health technology throughout ��ֳ� will allow us to continue to adapt, innovate and address specific unmet needs for people living with epilepsy, such as seizure prediction and coordination of care. Our leadership in epilepsy will remain cemented ensuring we continue to enjoy the competitive advantage gained in areas such as in development collaborations, inorganic opportunities and commercial endeavors.

Seizures, especially focal seizures remain difficult to track and record. Sometimes patients are not sure if they are actual seizures and at other times, they may have mental capability challenges which impede memory. This can make it difficult for HCPs to ascertain a patient’s progress and ensure the right treatment protocol. Our relationship with Byteflies is an exciting opportunity to alleviate this pain-point by providing a discreet wearable electroencephalogram device which enables detection of focal seizures. It’s a differentiated and highly valuable need for patients and HCPs to address concerns and ensure optimized treatment.

The unpredictable nature of epilepsy means that many people living with the disorder remain uncertain of when they will experience their next seizure. This can lead to a significant impact on a person’s quality of life and result in anxiety associated with the fear of experiencing another seizure. This issue could be addressed by simply providing patients with a warning. We continue to focus on seizure prediction as a key to unlock one of the biggest keys in epilepsy: knowing when a seizure is coming and potentially giving enough window to stop the seizure onset. We have partnered externally to begin developing a multimodal seizure prediction system while remaining vigilant for other opportunities in this developing landscape.

In addition to this unpredictability of seizures, there is also inherent unpredictability of treatment as ASMs don’t work universally. Many patients with epilepsy live with a level of uncertainty of whether they are on the right management plan. A recent publication demonstrated the importance of combining machine learning-based data to predict the clinical drug response, suggesting that artificial intelligence can act as a signpost for precision medicine. By partnering on digital solutions to coordination of care, we can begin to streamline the epilepsy management process.

��ֳ�’s recent investment in Nile AI, provides a personalized management platform, allowing patients to coordinate their regimen and track their progress. By pulling together the available data, it is our ambition to make the epilepsy journey more predictable. In addition to this, ��ֳ� has invested in prediction analytics to help patients to determine if they are likely to be resistant to treatment which can help to create a more efficient management pathway much earlier.

At ��ֳ�, we are driven to improve the lives of people living with epilepsy. The epilepsy community is at the forefront of everything we do, and our commitment has never been stronger. Utilizing our experience and expertise, combined with the development of health technology support solutions, we’re excited to fuel the future of epilepsy and provide solutions that people living with epilepsy desperately need.

about ucb

Epilepsy Nile AI International Epilepsy Congress Byteflies

929 Likes

Creating meaningful partnerships to alleviate the global burden of epilepsy

eCMSadmin — Mon, 30 Aug 2021 08:00:00 +0000

Creating meaningful partnerships to alleviate the global burden of epilepsy

Simon Borghs, Global Epilepsy Strategy

eCMSadmin Mon 30/08/2021 - 10:00

Epilepsy is an age-old disease that affects people around the globe. Over the last 100 years, huge steps have been taken in managing it, and many people with epilepsy are now free of seizures. In the last 30 years, ��ֳ� has played an important role in improving treatments, becoming the leader in epilepsy innovation among pharmaceutical companies.

Despite this significant evolution in care, there is still an opportunity to alleviate the global burden of epilepsy. In low- and middle-income countries (LMICs), 40 million people have epilepsy and 75% of these people do not get the treatment they need to manage their seizures. We must find new social business approaches that will allow us to enable easier access to epilepsy care via partnership models, and provide affordable treatments to underserved epilepsy patients. In 2021, we will launch a social business pilot in India; pilots in other high unmet need countries will follow.

Even in affluent countries, people with epilepsy are often underserved and may face barriers to access the medicine they need. Solving their barriers to access in a way that is viable for patients, society and ��ֳ�, will require tackling a combination of economic, technological, scientific, and systemic challenges.

At ��ֳ�, we are convinced that meaningful change in how we address these challenges requires collaboration across areas of expertise and stakeholder types. New care delivery models, and new ways of assessing value, need to be built. We are keen on sharing our connections, knowledge, data and experience, and partnering with key players in- and outside the healthcare system in areas where they have legitimacy and agency.

One example of a partnership in LMICs that aims to strengthen the healthcare system in a country with a uniquely high disease burden is between University of Ghent and the government of Rwanda, supported by the ��ֳ� CSR Fund, that aims to establish a medical curriculum at university level that will allow to train and build a sustainable pipeline of qualified neurologists. This will allow people living with epilepsy in Rwanda to have access to better healthcare.

In mature healthcare systems, ��ֳ� is exploring partnerships to reduce risk in the system. This will involve co-creating evidence to target the right patients and demonstrate the value of our treatments; collaborating with payers on value based contracts; and identifying and resolving structural access barriers where possible. In addition, for many years, ��ֳ� has collaborated with hospitals and academic centres on research projects that aim to improve care pathways and outcomes for epilepsy patients, and with patient organizations to arrange support; new activities aimed at underserved patients will be an extension of that.

Through our history and leadership, ��ֳ� is uniquely positioned to create meaningful and sustained value and therefore help build a better future for people living with epilepsy. Over the last 30 years, we have built connections, experience, data and knowledge that we can share with external partners. Going forward, given our position as a trusted partner in epilepsy, ��ֳ� can contribute to meaningful transformation of outcomes in epilepsy through a sustainable business approach.

For more information on ��ֳ�’s sustainability approach, visit: /our-company/Sustainability

about ucb

Epilepsy International Epilepsy Congress 2021 CSR Fund

708 Likes

Evolving the epilepsy treatment paradigm

eCMSadmin — Sun, 29 Aug 2021 08:00:00 +0000

Evolving the epilepsy treatment paradigm

Konrad Werhahn, Global Epilepsy Strategy

eCMSadmin Sun 29/08/2021 - 10:00

This weekend, the world’s leading clinicians and researchers will come together to exchange a wealth of knowledge at this year’s International Epilepsy Congress. Despite being held in a virtual setting, the congress is a pivotal opportunity for the brightest minds to connect and discuss new innovative solutions for people living with epilepsies. As such, we are proud to be at the forefront of those conversations and identifying new ways to treat epilepsy.

The epilepsies are common group of neurological disorders which are associated with physical and psychological difficulties, leading to a detrimental impact on a person’s quality of life. People who continue to have seizures are at greater risk of several complications, which is why preventing seizures is so important. Despite the significant advancements in treatment options, people living with epilepsy still need to consider the impact that their seizures can have on different aspects of their life.

At ��ֳ�, we understand that more needs to be done to provide further value for patients living with epilepsy. We are continually looking for innovative ways to provide new options for people living with epilepsy, and our strong research capabilities are allowing us to open the door for new future solutions, such as treating the underlying pathophysiology of a given epilepsy syndrome rather than seizures as its symptoms.

Treating underlying disease mechanisms is the final goal of any medical area. In the epilepsies, this is usually not feasible since the vast majority of current treatment options are symptomatic. Tackling this gap would be a break-through and transform the lives of people with the disease beyond suppression of seizure symptoms. Such a paradigm shift of moving from a purely symptomatic to a disease-modifying approach has the potential to transform the field. We strongly believe that delivering molecularly targeted treatment options will provide game changing efficacy for the patients with seizures.

To reach this ambition, we are starting from the patient pathophysiology combined with genomics to identify better validated targets. Using computational design and artificial intelligence we aim to more efficiently identify compounds that have a higher chance of leading to effective therapies. In doing so, we will open the door for new therapeutic modalities, such as gene therapy, as targeted treatment options for monogenic epilepsies and epilepsies with focal structural etiologies. While this is still a very early stage of development, it is exciting to be at the forefront of this potential evolution of the treatment paradigm.

For more than 30 years, ��ֳ� has played a critical role in providing new innovate options for people living with epilepsy. We have provided solutions that have helped transform the treatment landscape and improved the lives of millions of people living with epilepsy. However, we understand that the job is nowhere near finished. We’re driving for new solutions, helping us strive for symptom freedom today, anti-epileptogenic options tomorrow.

For more information on our research capabilities visit: /our-science/Overview

about ucb

Epilepsy International Epilepsy Congress IEC

857 Likes

International Epilepsy Day 2021: Reflecting on our journey and stepping into the future of epilepsy

eCMSadmin — Mon, 08 Feb 2021 00:00:00 +0000

International Epilepsy Day 2021: Reflecting on our journey and stepping into the future of epilepsy

Charl Van Zyl, Patient Value Neurology & Europe/International Solutions

eCMSadmin Mon 08/02/2021 - 01:00

Today marks International Epilepsy Day (IED), a special day where people from around the world come together to raise awareness of epilepsy and the challenges faced by patients, their families and carers. Recognized on the second Monday of February every year, this day provides a platform for 65 million people affected worldwide who are living with the disease.

Epilepsy is a chronic brain disorder characterized by recurrent seizures that affects people of all ages. The epilepsies are very heterogenous and consist of several hundred diseases or syndromes, which can lead to a myriad of physical consequences. Greater still, the psychological and social impact of living with epilepsy can be detrimental for a person’s quality of life; particularly in recent times with the isolating consequences of COVID-19. Recent studies indicated that while the risk of COVID-19 in patients with epilepsy is not thought to be higher than in healthy people, psychological stress from COVID-19 has been reported to be greater in people living with epilepsy. As such, initiatives such as IED remain invaluable to raise the profile of the fourth most common neurological condition in the world.

This year’s IED initiative challenged individuals to increase the visibility of epilepsy by taking part in the “50 million steps for epilepsy” walking challenge; a campaign which aims to increase the understanding the journey that people living with the disease take each and every day. The path that patients need to take is often a long one; despite the accessibility of treatments, one-third of newly diagnosed epilepsy patients remained untreated up to three years after their diagnosis. At ��ֳ�, we are committed in reducing this path to seizure control and have been driven to finding a solution for many years.

With over 20 years of research and development of novel anti-epileptic drugs (AEDs), we strive to use expertise, knowledge and resources to improve epilepsy care and meet the diverse needs of people living with the condition. However, despite the significant developments over the years, our team recognizes that more must be done to narrow the treatment gap and improve patient experiences.

“At ��ֳ�, we aspire for better outcomes and experiences to help patients live their ideal lifestyle, striving for freedom of symptoms today and anti-epileptogenic options tomorrow. Our overarching ambition is to provide sustainable patient value via a diverse core of differentiated medicine-based and technology-leveraged solutions that address patient need and deliver better outcomes,” added Alexandre Moreau, Global Head of Epilepsy at ��ֳ�.

While we have taken tremendous steps over the last 20 years, there still remains a long road ahead to deliver the level of care that we aspire to achieve. As such, we find ourselves entering a new era of epilepsy management where new avenues are leading us to alternative solutions. With plenty of work still at hand, we are a passionate to continue our journey in providing the most efficient care for those most in need. Such avenues include:

Partnering to meet unmet needs: Through our investment in Nile AI, Inc., who is developing a digital epilepsy care management platform and bringing together data to make the epilepsy journey predictable, there are future opportunities to acquire insights and data from Nile’s platform.
Delivering scientific innovation: We’re contributing to cutting-edge research in epilepsy that may help pave the way for future treatment options. We’re embracing the convergence of science, medicine and technology by exploring exciting new approaches which, in the future, could provide individually tailored solutions for people with epilepsy.
Sustainable access to treatment: The treatment gap in epilepsy is not a phenomenon confined to developing countries, but an issue that is also prominent in high-income nations, and one that needs to be addressed. We are dedicated to the goal of ensuring that all patients have access to individualized solutions tailored to their individual needs.

As we continue our path to improve experiences for people living with epilepsy, we are excited to be at the forefront of new collaborative solutions to provide the best access of care in one form or another. While many obstacles lie in the path ahead, one thing is for certain, ��ֳ� will be there every step of the way. Keep an eye out on ��ֳ�’s social channels for more insights on our progress in epilepsy management.

solutions

Epilepsy International Epilepsy Day

819 Likes

Supporting International Epilepsy Day 2020

eCMSadmin — Mon, 10 Feb 2020 08:30:00 +0000

Supporting International Epilepsy Day 2020

Konrad Werhahn, Global Epilepsy Strategy

eCMSadmin Mon 10/02/2020 - 09:30

Today is International Epilepsy Day, a day where people from around the world come together to raise awareness of epilepsy and the challenges faced by patients, their families and carers. Over 65 million people live with epilepsy worldwide yet despite this and the available treatments, public fear and misunderstanding about epilepsy persists and the treatment gap remains high. At ��ֳ�, we are proud to be sponsors of International Epilepsy Day and remain devoted to improving the lives of those affected by epilepsy around the globe. Read on to find out about ��ֳ�’s commitment to epilepsy and our current research on the treatment gap in new onset epilepsy.

In a previous blog post, my colleague Cédric Laloyaux, Global Medical Lead, - Neurology, spoke about how ��ֳ� had embarked on a new global initiative aiming to improve real-world outcomes for people living with epilepsy. Since then, as part of the ��ֳ� Epilepsy Outcomes Project (EOP), the team has continued to collaborate with experts to assess the epilepsy treatment gap. One collaboration, the results of which were published in Neurology, was a retrospective study of newly diagnosed epilepsy patients in the U.S. and the effects the lack of treatment may have on health outcomes. This followed on from an initial editorial piece in The Lancet which highlighted the factors contributing to why people with epilepsy often don’t receive the care they require.

The retrospective analysis found that one-third of newly diagnosed epilepsy patients remained untreated up to three years after their diagnosis. Previous studies have focused on low-income nations and have reported treatment gaps of up to 95%, yet this study strongly suggests that the treatment gap in epilepsy is present not only in developing countries, but also high-income countries where antiepileptic drugs (AEDs) are readily available.

It was found that compared to treated patients, untreated epileptic patients are 20% more likely to encounter a medical event associated with epilepsy such as; burns, falls, fractures, motor accidents and suicidality. Unsurprisingly, patients not receiving treatment for their epilepsy were also at a greater than two-fold increased risk of hospitalizations, and emergency department visits, suggesting that untreated epilepsy results in medical events necessitating increased use of health care resources.

Given the impact on patient outcomes and healthcare resources, such a significant treatment gap should be seen as worrisome. As the authors conclude, the treatment gap in epilepsy is not a phenomenon confined to developing countries, but an issue that is also prominent in high-income nations, and one that needs to be addressed.

This collaboration is one of the first steps in the EOP initiative, which aims to identify and analyse communication gaps between patients and healthcare professionals about epilepsy and epilepsy treatments, factors leading to treatment gaps related to AED selection initiation, and epilepsy diagnosis in emergency departments. Identifying a gap in epilepsy treatment and assessing some of the reasons for this is one step towards improving access to care and quality of life for patients with epilepsy.

��ֳ� remains committed to improving experiences for people with epilepsy and progress towards eradicating the impact of epilepsy around the world. Keep an eye out on ��ֳ�’s Twitter and Facebook pages for more insights on the epilepsy treatment gap.

solutions

Epilepsy The Lancet International Epilepsy Day

600 Likes

Epilepsy

Epilepsy Awareness Month: Increasing Knowledge, Support and Advocacy

Leave a Comment

Sudden Unexpected Death in Epilepsy: our commitment to supporting families and patients

Leave a Comment

��ֳ� welcomes the epilepsy treatment updates to the WHO Model List of Essential Medicines

Leave a Comment

Meeting unmet needs in epilepsy management through digital health technological solutions

Leave a Comment

Creating meaningful partnerships to alleviate the global burden of epilepsy

Leave a Comment

Evolving the epilepsy treatment paradigm

Leave a Comment

International Epilepsy Day 2021: Reflecting on our journey and stepping into the future of epilepsy

Leave a Comment

Supporting International Epilepsy Day 2020

Leave a Comment

Epilepsy

Epilepsy Awareness Month: Increasing Knowledge, Support and Advocacy

Leave a Comment

Sudden Unexpected Death in Epilepsy: our commitment to supporting families and patients

Leave a Comment

������ֳ� welcomes the epilepsy treatment updates to the WHO Model List of Essential Medicines

Leave a Comment

Meeting unmet needs in epilepsy management through digital health technological solutions

Leave a Comment

Creating meaningful partnerships to alleviate the global burden of epilepsy

Leave a Comment

Evolving the epilepsy treatment paradigm

Leave a Comment

International Epilepsy Day 2021: Reflecting on our journey and stepping into the future of epilepsy

Leave a Comment

Supporting International Epilepsy Day 2020

Leave a Comment

��ֳ� welcomes the epilepsy treatment updates to the WHO Model List of Essential Medicines